{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:19:37Z","timestamp":1781799577537,"version":"3.54.5"},"reference-count":13,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,12]]},"DOI":"10.1182\/bloodadvances.2023011295","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T20:11:07Z","timestamp":1697487067000},"page":"7235-7238","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Acquired <i>CD38<\/i> gene deletion as a mechanism of tumor antigen escape in multiple myeloma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"first","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"},{"name":"2University of Washington, Department of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"},{"name":"2University of Washington, Department of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherilyn A.","family":"Tuazon","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"},{"name":"3Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Pont","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"},{"name":"4CellPoint Bio, a Galapagos company, Oegstgeest, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Qu","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"},{"name":"2University of Washington, Department of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Shasha","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Comstock","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justina","family":"Lyons","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Cole","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"},{"name":"4CellPoint Bio, a Galapagos company, Oegstgeest, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan W.","family":"Newell","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"},{"name":"2University of Washington, Department of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Glynn","sequence":"additional","affiliation":[{"name":"2University of Washington, Department of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorinda A.","family":"Soma","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"},{"name":"5City of Hope Medical Center, Department of Pathology, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1446","authenticated-orcid":false,"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA"},{"name":"2University of Washington, Department of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"2023121220231317300_bib1","unstructured":"Sarclisa (isatuximab). Package insert. sanofi-aventis U.S. LLC. 3\/2020. Accessed  May 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761113s000lbl.pdf."},{"key":"2023121220231317300_bib2","unstructured":"Darzalex (daratumumab). Package insert. Janssen Biotech, Inc. 3\/2022. Accessed  October 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761036s041lbl.pdf."},{"issue":"9","key":"2023121220231317300_bib3","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"2023121220231317300_bib4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"2023121220231317300_bib5","first-page":"1234","article-title":"The phenotype of normal, reactive and malignant plasma cells. Identification of \"many and multiple myelomas\" and of new targets for myeloma therapy","volume":"91","author":"Bataille","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"2023121220231317300_bib6","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"2023121220231317300_bib7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2023121220231317300_bib8","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clml.2016.02.037","article-title":"Loss of CD38 expression in relapsed refractory multiple myeloma","volume":"16","author":"Ise","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2023121220231317300_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/ejh.12902","article-title":"CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy","volume":"99","author":"Minarik","year":"2017","journal-title":"Eur J Haematol"},{"issue":"9","key":"2023121220231317300_bib10","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.169235","article-title":"Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection","volume":"102","author":"Oberle","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"2023121220231317300_bib11","first-page":"221","article-title":"VS38 identifies myeloma cells with Dim CD38 expression and plasma cells following daratumumab therapy, which interferes with CD38 detection for 4 to 6\u00a0months","volume":"153","author":"Courville","year":"2020","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"2023121220231317300_bib12","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/trf.17137","article-title":"Anti-CD38 monoclonal antibody interference with blood compatibility testing: differentiating isatuximab and daratumumab via functional epitope mapping","volume":"62","author":"Chami","year":"2022","journal-title":"Transfusion"},{"issue":"6","key":"2023121220231317300_bib13","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7235\/2176350\/blooda_adv-2023-011295-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7235\/2176350\/blooda_adv-2023-011295-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T20:23:32Z","timestamp":1702412612000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/23\/7235\/498329\/Acquired-CD38-gene-deletion-as-a-mechanism-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":13,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011295","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}